First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease

Conclusion: The current study suggested that the addition of LAT to EGFR-TKI could provide satisfactory survival benefit for EGFR-mutant NSCLC patients with oligoprogression during first-line EGFR-TKI treatment.

Source: Journal of Cancer - June 13, 2019 Category: Cancer & Oncology Authors: Qinghua Xu, Hui Liu, Shuyan Meng, Tao Jiang, Xuefei Li, Shixiong Liang, Shengxiang Ren, Caicun Zhou Tags: Research Paper Source Type: research